NCT04924179Unknown2 期
A Phase II, Single-arm, Open-label, Single Center Study of Tislelizumab Combined With Fruquintinib and SBRT as A Third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
A Phase II Study to Assess the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With Advanced Colorectal Cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of written Informed Consent Form (ICF) prior to any study specific procedures
- •Age ≥ 18 years, ≤75 years
- •Histologically or cytologically confirmed advanced Stage IV primary colorectal cancer
- •One or more organs metastases, and the metastases are suitable for SBRT according to the evaluation of the researchers;
- •At least two or more standard systemic therapies prior treatment (based on Fu, oxaliplatin, irinotecan, bevacizumab and cetuximab) of cytotoxic chemotherapy, treatment failure or intolerable toxicities
- •Patients must have measurable lesions
- •Expected overall survival ≥12 weeks
- •AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum bilirubin ≤ 1.5 x ULN，creatinine<ULN
- •Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN
- •Patients are allowed to have received radiotherapy, but the time from entering the group must be more than 4 weeks, and the currently selected radiotherapy lesions and evaluable lesions must be lesions that have not received radiotherapy
- •Women of childbearing age must be willing to use adequate contraceptives during the study period of drug treatment
排除标准
- •Patients have received anti-PD-1 / PD-L1 immunotherapy or other immunoexperimental drugs
- •Patients with severe autoimmune diseases: active inflammatory bowel disease (including Crohn's disease and ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (such as Wegener's granuloma), etc
- •Risk factors of intestinal perforation: active diverticulitis, abdominal abscess, gastrointestinal obstruction, abdominal cancer or other known risk factors of intestinal perforation
- •Known hereditary or acquired bleeding (such as coagulation dysfunction) or thrombotic tendency, such as hemophilia patients
- •Aspirin (> 325 mg / day (maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel (≥ 75 mg) and cilostazol are currently used or have been used recently (within 10 days before the start of study treatment)
- •Thrombosis or embolism events such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction) and pulmonary embolism occurred within 6 months before the start of the study
- •The researchers believe that the patient has a lesion and needs emergency palliative radiotherapy / emergency surgery (spinal cord compression, brain hernia, pathological fracture)
- •Known active infection and active tuberculosis infection were not included in the group; However, patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection can be included in the group if their condition is stable after antiviral treatment;
- •There is evidence of pneumoperitoneum that cannot be explained by puncture or recent surgery;
- •Patients with history of hepatic encephalopathy;
- •Participated in the clinical trials of other drugs that have not been approved or marketed in China and received the corresponding experimental drug treatment within 2 weeks before enrollment
- •systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg regardless of any antihypertensive drugs; Or patients need more than two antihypertensive drugs
- •Patients have untreated central nervous system metastasis
- •Received any operation or invasive treatment or operation (except venous catheterization, puncture and drainage, etc.) within 4 weeks before enrollment
- •Patients have not recovered from all toxicities associated with prior anti-tumor therapy ,to acceptable baseline status, or a National Cancer Institute Common Terminology Criteria for Adverse Events(NCI CTCAE v5.0) Grade of 0 or 1, except for alopecia and oxaliplatin induced neurotoxicity ≤ 2 , and the previous surgery did not recover completely
- •Dysphagia or known malabsorption of drugs
- •Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in GI
- •Have evidence or history of bleeding tendency within 2 months after enrollment, the researcher assessed that moderate or severe bleeding tendency was not suitable for enrollment
- •Patients had other malignant tumors in the past 5 years or at the same time (except for the cured skin basal cell carcinoma and cervical carcinoma in situ);
- •Pregnant or lactating women
- •Allergic to Surufatinib/Vinorelbine
- •History of immunodeficiency, including HIV positive, other acquired or congenital immunodeficiency diseases, or organ transplantation
- •Patients with acute myocardial infarction, severe / unstable angina pectoris or coronary artery bypass grafting within 6 months before admission; Or a history of arterial thrombosis or deep venous thrombosis
- •There are concomitant diseases (such as severe hypertension, diabetes, thyroid disease, active infection, etc.) that seriously endanger the safety of patients or affect the completion of the study, or any laboratory abnormalities that are not suitable for participating in the clinical trial according to the judgment of the researcher
- •Active autoimmune disease or history of autoimmune disease with possible recurrence (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism);
- •Immunosuppressive agents or systemic hormones were used 14 days before the start of the study to achieve the purpose of immunosuppression (dose > 10mg / day prednisone or other therapeutic hormones)
- •Known to have a history of severe allergy to any monoclonal antibody or antiangiogenic target drug
- •Serious psychological or mental disorders that may affect the compliance study
研究组 & 干预措施
Tislelizumab plus Fruquintinib and SBRT
Experimental
干预措施: Tislelizumab plus Fruquintinib and SBRT (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: up to 16 months
To assess the efficacy of Tislelizumab Combined With Fruquintinib and SBRT for patients with advanced colorectal cancer by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
次要结局
- Disease control rate (DCR)(up to 16 months)
- Objective response rate (ORR)(up to 16 months)
- Overall survival (OS)(up to 36 months)
- AEs(up to 36 months)
研究者
Xianglin Yuan
Huazhong University of Science and Technology
Huazhong University of Science and Technology
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT04956146The First Affiliated Hospital with Nanjing Medical University46
尚未招募
2 期
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver MetastasesColo-rectal CancerNCT06218888Fujian Cancer Hospital17
尚未招募
2 期
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced CancerGastric CancerNCT06094868Second Affiliated Hospital of Nanchang University45
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center StudyHigh-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNCT05418309Tianjin Medical University Second Hospital63
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableHigh-RiskNon-Muscle Invasive Bladder Urothelial CarcinomaNCT04730232Tianjin Medical University Second Hospital63